Keytruda

In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
In new PD-1 showdown, GSK's Jemperli loses initial edge on Merck's Keytruda
Fierce Pharma
GSK
Merck
Keytruda
Jemperli
cancer
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Merck's TIGIT fails in phase 2 Keytruda combo, notching another loss for the class
Fierce Biotech
Merck
Keytruda
clinical trials
vibostolimab
non-small cell lung cancer
metastatic non-small cell lung cancer
Flag link:
Keytruda Unlocked: How Should Merck Proceed with Trials?
Keytruda Unlocked: How Should Merck Proceed with Trials?
BioSpace
Keytruda
Merck
cancer
clinical trials
Flag link:
Merck reports positive data from malignant pleural mesothelioma trial
Merck reports positive data from malignant pleural mesothelioma trial
Clinical Trials Arena
Merck
Canadian Cancer Trials Group
clinical trials
Keytruda
mesothelioma
Flag link:
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
In PD-1 rivalry, Merck's Keytruda catches up with Opdivo in rare lung cancer type
Fierce Pharma
Merck
Keytruda
Opdivo
Bristol Myers Squibb
pleural mseothelioma
mesothelioma
clinical trials
Flag link:
Merck reports two Phase 3 study misses for Keytruda
Merck reports two Phase 3 study misses for Keytruda
BioPharma Dive
Merck
clinical trials
Keytruda
prostate cancer
lung cancer
Flag link:
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Fierce Biotech
cancer
Biocytogen
Chipscreen NewWay Biosciences
Merck
Keytruda
YH008
Flag link:
Warren urges US patent office to scrutinize Merck's efforts with Keytruda
Warren urges US patent office to scrutinize Merck's efforts with Keytruda
Fierce Pharma
Merck
Keytruda
Senate
Elizabeth Warren
patents
Flag link:
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’
BioPharma Dive
Big Pharma
patents
patent cliff
biosimilars
AbbVie
Humira
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Flag link:
Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow
Merck targets BMS' stomach cancer head start with Keytruda win, but past failure casts shadow
Fierce Pharma
Merck
Keytruda
clinical trials
stomach cancer
Flag link:
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program
Fierce Biotech
Merck
Keytruda
prostate cancer
Flag link:
The end of the Humira era
The end of the Humira era
EP Vantage
AbbVie
Humira
patents
biosimilars
Merck
Keytruda
Flag link:
A Hit and a Miss for Merck’s Keytruda
A Hit and a Miss for Merck’s Keytruda
BioSpace
Merck
Keytruda
prostate cancer
biliary tract cancer
Flag link:
Immuno-oncology goes subcutaneous
Immuno-oncology goes subcutaneous
EP Vantage
immuno-oncology
oncology
subcutaneous drug delivery
Keytruda
Merck
Tecentriq
Roche
Flag link:
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Merck
Keytruda
Roche
cancer
oncology
Flag link:
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Flag link:
Merck Highlights Growth Strategy at J.P. Morgan
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Merck
JPMHC 2023
Keytruda
vaccines
M&A
Flag link:
OncoC4 doses first participant in ovarian cancer therapy trial
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Flag link:

Pages